PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway.
PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway.
BMJ Open. 2022 Sep 30;12(9):e061159. doi: 10.1136/bmjopen-2022-061159.
To investigate the perceived risk of psychotropic and mental illness exposures (1) during pregnancy or (2) while breastfeeding on offspring neurodevelopment, and factors associated with this perception in women with past/current mental illness.
Cross-sectional, web-based study.
Nationwide in Norway, June 2020-June 2021.
Women aged 18-55 years who were pregnant, recent mothers or planning a pregnancy, and had been offered antidepressants in the last 5 years.
Perceived risk of prenatal and breastmilk exposure to psychotropic medications and maternal mental illness on offspring neurodevelopmental outcomes.
We included 448 women: 234 pregnant, 146 mothers and 68 planning a pregnancy. On a 0-10 scale, women perceived antidepressants as least harmful both (1) in pregnancy (mean score 4.2, 95% CI 3.6 to 4.8) and (2) while breastfeeding (mean score 3.8, 95% CI 3.3 to 4.4), relative to antipsychotics, anxiety/sleeping medication or antiepileptics (mean score range: 6.3-6.5 during pregnancy, 5.5-6.2 while breastfeeding). Many participants were unfamiliar with psychotropics other than antidepressants. The perceived risk of mental illness exposure exceeded that of antidepressants (mean score range 5.6-5.9) in both exposure periods. Using general linear models, factors associated with greater antidepressant risk perception in both exposure periods included having lower education, non-Norwegian native language, and employment status (range mean score difference (β): 2.07-6.07). For pregnant women and mothers, there was an inverse association between perceived risk and the perceived antidepressant effectiveness in both exposure periods (range of β: -0.18 to -0.25).
In women with past/current mental illness, the perceived risk of antidepressant exposure on child neurodevelopment was lower than that for maternal mental illness. Other psychotropic medications were perceived as more harmful. As medication risk perception influences the decision-making regarding treatment of mental illness, pre- and pregnancy counselling should target women with characteristics associated with higher perceived risk.
调查(1)怀孕期间或(2)哺乳期接触精神药物和精神疾病对后代神经发育的感知风险,以及有过去/当前精神疾病史的女性对这种感知的相关因素。
横断面、基于网络的研究。
2020 年 6 月至 2021 年 6 月,挪威全国范围。
年龄在 18-55 岁之间、怀孕、最近分娩或计划怀孕、且在过去 5 年内曾被开抗抑郁药的女性。
怀孕期间和哺乳期接触精神药物和产妇精神疾病对后代神经发育结果的感知风险。
我们纳入了 448 名女性:234 名孕妇、146 名产妇和 68 名计划怀孕的女性。在 0-10 分的评分中,与抗精神病药、焦虑/睡眠药物或抗癫痫药相比,女性认为抗抑郁药在(1)怀孕期间(平均得分 4.2,95%置信区间 3.6 至 4.8)和(2)哺乳期(平均得分 3.8,95%置信区间 3.3 至 4.4)的危害最小(平均得分范围:怀孕期间 6.3-6.5,哺乳期 5.5-6.2)。许多参与者不熟悉抗抑郁药以外的精神药物。在两个暴露期内,产妇精神疾病暴露的感知风险都超过了抗抑郁药(平均得分范围 5.6-5.9)。在两个暴露期内,与抗抑郁药风险感知增加相关的因素包括教育程度较低、非挪威母语和就业状况(平均得分差异(β)范围:2.07-6.07)。对于孕妇和产妇,在两个暴露期内,感知风险与感知抗抑郁药有效性之间呈负相关(β范围:-0.18 至 -0.25)。
在有过去/当前精神疾病史的女性中,抗抑郁药暴露对儿童神经发育的感知风险低于产妇精神疾病。其他精神药物被认为危害更大。由于药物风险感知会影响治疗精神疾病的决策,因此在怀孕前和怀孕期间的咨询应针对具有更高感知风险特征的女性。